Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Satoshi Ikeda, MD, PhD"'
Autor:
Daisuke Hazama, MD, PhD, Kenji Nakahama, MD, PhD, Hiroaki Kodama, MD, Akito Miyazaki, MD, Koichi Azuma, MD, PhD, Yosuke Kawashima, MD, Yuki Sato, MD, Kentaro Ito, MD, Yoshimasa Shiraishi, MD, Keita Miura, MD, Takayuki Takahama, MD, PhD, Satoshi Oizumi, MD, PhD, Yoshinobu Namba, MD, Satoshi Ikeda, MD, PhD, Hiroshige Yoshioka, MD, PhD, Asuka Tsuya, MD, PhD, Yuichiro Yasuda, MD, PhD, Yoshiki Negi, MD, PhD, Ayako Hara, MD, Michihito Toda, MD, PhD, Motoko Tachihara, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 1, Pp 100613- (2024)
Introduction: Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of lung cancer associated with poor prognosis and resistance to conventional chemotherapy. Immune checkpoint inhibitors (ICIs), alone or in combination with chemotherapy, were foun
Externí odkaz:
https://doaj.org/article/ceb8623f26cd4608b0d8ffd019ba6537
Autor:
Kazushige Wakuda, MD, Hiroyuki Yamaguchi, MD, PhD, Hirotsugu Kenmotsu, MD, PhD, Minoru Fukuda, MD, PhD, Kentaro Ito, MD, Yuko Tsuchiya-Kawano, MD, PhD, Kentaro Tanaka, MD, PhD, Taishi Harada, MD, PhD, Yuki Nakatani, MD, Satoru Miura, MD, Toshihide Yokoyama, MD, Tomomi Nakamura, MD, Miiru Izumi, MD, PhD, Atsushi Nakamura, MD, PhD, Satoshi Ikeda, MD, PhD, Koichi Takayama, MD, PhD, Kenichi Yoshimura, PhD, Kazuhiko Nakagawa, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Kenji Sugio, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100587- (2023)
Introduction: Osimertinib may be effective in treating central nervous system (CNS) metastasis, but its efficacy in treating radiation therapy (RT)-naive metastasis is unclear. The OCEAN study assessed the efficacy of osimertinib against RT-naive CNS
Externí odkaz:
https://doaj.org/article/2430d3ab5e8943f5b2079f35a13f2fad
Autor:
Satoshi Ikeda, MD, PhD, Akimasa Sekine, MD, PhD, Tomohisa Baba, MD, Terufumi Kato, MD, Takuma Katano, MD, Erina Tabata, MD, Ryota Shintani, MD, Hideaki Yamakawa, MD, PhD, Tsuneyuki Oda, MD, PhD, Ryo Okuda, MD, Hideya Kitamura, MD, PhD, Tae Iwasawa, MD, PhD, Tamiko Takemura, MD, PhD, Takashi Ogura, MD, Jorddy Neves Cruz.
Publikováno v:
Medicine, Vol 101, Iss 22, p e29232 (2022)
Abstract. Introduction:. A subgroup analysis of the CAPACITY and ASCEND trials showed that pirfenidone use beyond disease progression reduced the risk of subsequent forced vital capacity (FVC) decline and death. Our study aimed to compare the efficac
Externí odkaz:
https://doaj.org/article/36d89725e3a04902b552d6bb3541de74
Autor:
Makoto Nishio, MD, PhD, Kazuto Nishio, MD, PhD, Martin Reck, MD, PhD, Edward B. Garon, MD, Fumio Imamura, MD, PhD, Tomoya Kawaguchi, PhD, Hiroyuki Yamaguchi, MD, PhD, Satoshi Ikeda, MD, PhD, Katsuya Hirano, MD, Carla Visseren-Grul, MD, Matteo Ceccarelli, PharmD, MS, Sameera R. Wijayawardana, PhD, Annamaria Zimmermann, MS, Tomoko Matsui, Sotaro Enatsu, MD, PhD, Kazuhiko Nakagawa, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 4, Pp 100303- (2022)
Introduction: Ramucirumab (RAM) plus erlotinib was found to have superior progression-free survival (PFS) versus placebo plus erlotinib in untreated EGFR-mutated metastatic NSCLC in the global phase 3 RELAY study. RELAY+ was an open-label, two-period
Externí odkaz:
https://doaj.org/article/2c15ffbd66fc4dc2bedf92f859b0dd3f
Autor:
Satoshi Ikeda, MD, PhD, Hiromasa Arai, MD, PhD, Akimasa Sekine, MD, PhD, Koji Okudela, MD, PhD, Tae Iwasawa, MD, PhD, Takashi Ogura, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 3, Pp 100043- (2020)
Externí odkaz:
https://doaj.org/article/a2e8983df8374fc19d032631eebbb160